Teleflex Incorporated Company Overview NYSE: TFX

Transcription

1 Teleflex Incorporated Company Overview NYSE: TFX

2 Forward Looking Statements 2 This presentation and our discussion contain forward-looking information and statements including, but not limited to, long-term goals and objectives of building on a strong operating platform, generating above-market-average revenue growth, capturing market share in key product areas and expanding gross and operating margins; expectations that our product pipeline in 2013 will be robust, that new product sales will contribute approximately 1% to 1.5% of 2013 revenue growth and that newly introduced products are expected to contribute positively to margins in 2013 and beyond; our expectation that current and future footprint rationalizations will improve operating margins in 2014 and 2015; our anticipated international product release of the Arrow VPS in Q1 2013; our expectation that our acquisition of LMA International N.V. and affiliates will be accretive to our 2013 adjusted earnings per share; our acquisition of Vidacare Corporation and its expected contribution to our 2014 revenue and adjusted earnings per share results; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward looking statements. These risks and uncertainties are addressed in the Company s SEC filings, including its most recent Form 10-K. The following slides reflect continuing operations.

3 Teleflex at a Glance 3 Leading global provider of medical devices with leading market positions Focused on critical care and surgical procedures Annual Revenues: $1.55 billion (2012) Serving healthcare providers in more than 140 countries Global operations: 25 countries Employees: 11,000+ organized into regions, divisions and global functions Established global sales and distribution network Well known brands in vascular access (including interventional access), anesthesia, respiratory care, urology, cardiac care and surgery Strong financial position

4 Our Story 4 Historically a diversified company, Teleflex has transformed its portfolio to become a pure play medical device company Began as a specialty engineering company 70 years ago More than 35 years in medical device Acquired established brands over time Established global medical device sales channels Strategic business unit structure: International (EMEA and Asia), Latin America, Anesthesia/Respiratory, Cardiac Care, OEM, Specialty, Surgical and Vascular Access

5 Teleflex Today 5 Vascular Access Surgical Specialty Cardiac Care Anesthesia / Respiratory OEM Central, Peripheral and Arterial Vascular Access Catheters Catheter Tip Positioning Systems Sheath Introducers Vascular Access Accessories Ligation Systems Closure Devices Laparoscopic Access Ports/Trocars General & Specialty Instruments Chest Drainage Systems CV Sutures Foley Catheters Intermittent Catheters Atomization Dialysis Catheters PTA Balloons Interventional Access Intra Aortic Balloon Pumps IAB Catheters TransRadial Access Right Heart Products Percutaneous Sheath Introducers Supraglottic Airways Atomization Epidurals Peripheral Nerve Blocks Airway Management Respiratory Therapy Specialty Sutures Catheter Fabrication Performance Fibers Custom Engineered Precision Extrusion ~$375 million ~$291 million ~$260 million ~$79 million ~$406 million ~$140 million Note: Figures represent 2012 revenues per Form 10K.

6 Our Markets 6 15% 51% 10% 6% 84% 34% United States Europe, Middle East, Africa Asia, Latin America and Canada Hospitals and Healthcare Providers Medical Device Manufacturers Home Health 2012 Revenue: $1.55 Billion Note: Amounts shown represent percentages of total revenues for the twelve months ended December 31, 2012, per Form 10K.

7 Our Products 7 5% 9% 19% 67% Critical Care Surgical Care Cardiac Care OEM Diversified, not dependent upon any single product or procedure Note: Amounts shown represent percentages of total revenues for the twelve months ended December 31, 2012, per Form 10K.

8 Key Elements of our Strategic Growth Plan 8 Pricing close the gap between ourselves and competitors Innovation new product introductions and line extensions Rationalization reduce facility footprint Investments key geographic, capital and R&D initiatives Acquisitions build the portfolio Service value proposition

9 Long-term Goals and Objectives 9 Build upon a strong operating platform Generate above-market-average revenue growth and capture market share in key product areas Expand gross and operating margins

10 Focus on Innovation: Key New Product Launches 10 Softech Plus Nasal Cannula Use: oxygen delivery Weck AE5 Use: automatic endo applier Weck Efx Use: Closure system Arrow FlexBlock Continuous Peripheral Nerve Block Catheter 4,5,6Fr IR PICC Use: peripheral inserted catheter for smooth insertion EZ Blocker Use: lung isolation and ventilation IR PICC w/ Chloragard Use: central venous catheter Hotspur GPS Cath Use: treatment of obstructive lesions 2012 Trans-Radial Use: artery cardiac catheter Arrow FlexTip Plus Multi-Port Epidural Catheter Pre-loaded PICC w/ ARROW VPS Use: replaces need for X-ray CE Mark Chronic Hemodialysis Use: dialysis access Weck Vista Balloon Expansion Use: entry into the preitoneum (abdomen) AT 510(k) on PICC Use: catheter with Chlorhexidine solution Weck Vista Optical Trocar Use: clear visualization of tissue layers ISO-Gard Circuit Technology Use: circuit condensation management CE Mark PICC & VPS Use: avoid thrombosis, arterial puncture and vessel wall damage Weck Vista Reposable Obturator Use: controlled entry Anesthesia/Respiratory Vascular Access Surgical International

11 Focus on Innovation 11 Robust product pipeline in 2013 Expectation that new product sales contribute ~ 1.0% to 1.5% of 2013 revenue growth Mix of newly introduced products expected to contribute positively to margins in 2013 and beyond

12 Margin Improvement Investments 12 A key to future gross and operating margin expansion is to reduce operational footprint, while balancing additional investments North American distribution center, Mount Holly, N.J. manufacturing, France distribution center consolidation announcements in 2012 are the first steps Additional footprint rationalization planned for the future Current and future footprint rationalization announcements expected to improve operating margin s in 2014 and 2015

13 Margin Improvement Investments 13 Limit the addition of commercial expenses to higher-growth geographies 1. China 2. Brazil Targeted information technology capital expenditure initiatives 1. Reduce future headcount through common processes Manage additional expenses associated with internal and external research and development initiatives holistically

14 Acquisition Approach 14 Fits into our existing strategic business unit franchises and call points Product provides a superior clinical benefit to existing alternatives Provides a cost benefit to a hospital Strong IP and patent protection Difficult for competitors to follow

15 ARROW VPS 15 Adoption of ARROW VPS in U.S. market continues CE Mark certification received on VPS International product release in Q1 2013

16 Semprus Biosciences (Sustain technology design) 16 Proteins, RBCs & Bacteria Protective Water Layer Semprus Sustain Polymer Medical Device Surface Semprus Sustain Technology Approximately 1 µm (1/100 th the Width of a Human Hair) Human Hair (~100 µm)

17 Hotspur Technologies 17

18 Weck EFx Endo Fascial Closure System 18 Endo Fascial Closure System designed for: Reproducible, uniform closure across patient anatomy Minimized risk of needle-stick injury Facilitates unassisted technique More than 750 clinical cases have been performed with the device in the United States Innovation of the Year -

19 EZ-Blocker TM 19 Acquired single-use catheter product line during 2nd quarter of 2012 Patented bronchial blocker for lung isolation and one-lung ventilation Addition to Rusch Airway portfolio Unique bifurcated distal end CE Mark approval obtained in Europe 510(k) approval September 2012

20 LMA International N.V. and affiliates 20 Global market leader in laryngeal masks Provides access to key clinical U.S. and international call points Further strengthens Group Purchasing Organization relationships Expected to be accretive to 2013 adjusted earnings per share

21 Ultimate Medical 21 A leading supplier and innovator of airway management devices, including a full-range of laryngeal mask airways Developed the Cuff Pilot TM, the world's first integrated cuff pressure indicator for airway management devices. This novel technology allows clinicians to continuously assess cuff pressure which may reduce the risk of aspiration and tracheal injury. Cuff Pilot TM technology is currently used with Ultimate Medical s portfolio of laryngeal masks and has potential application for use with LMA TM laryngeal masks

22 Eon Surgical 22 Late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons ability to perform scarless surgery while producing better patient outcomes Developed the InterTip platform, a complete solution for performing scarless laparoscopic surgery, that unlike single-port laparoscopy allows the surgeon to maintain the triangulation of standard laparoscopic surgery Technology is applicable to the majority of all laparoscopic surgical procedures and allows Teleflex to expand its offering for minimally invasive surgery Tools Intersleeve Camera Telescoping Needle with Handle

23 Vidacare Corporation 23 Company Overview Leading provider of intraosseous (IO), or inside the bone, access devices for diagnostic monitoring and therapeutic applications Based in Shavano Park, TX 87 issued and 8 pending patent applications Strategic Fit Expands vascular access product portfolio with a defining technology and moves TFX into the IO segment Strengthen EMS channel & Nursing call points High gross and operating margin profile Product Unique platform technology for immediate vascular access and bone marrow biopsy based driver system Razor/Razor blade model (Driver and Needle) Patented technology with strong brand equity

24 Vidacare Corporation 24 Intraosseous Infusion System for immediate vascular access Bone marrow aspirations, biopsies or harvesting Provides safe and rapid access to vertebrae during spinal surgery

25 Service 25 We want to be the partner of choice for all customers Significant improvement made during last two years 1. On-time deliveries to customers 2. Reduction of backorders Well-positioned with all major Group Purchasing Organizations and Integrated Delivery Networks

26 Why Will Teleflex Win? 26 Opportunity to generate above-market revenue growth rates 1. Not dependent upon any one product or geography 2. Not overly impacted by elective procedure downturns 3. Established, global distribution network 4. Near-term pricing opportunities 5. Mix of future new products Ability to improve profitability is within our control Our people!

27 Thank You